Conference Day 2019

The conference day includes executive panels outlining capital market dynamics, big pharma market appetite, clinical, regulatory and commercialisation drivers, finance raising & partnerships and emerging healthcare models.

There are also 3x intimate and practical workshops on clinical development, regulatory approval, licensing strategies and market access and reimbursement.


Registration and Breakfast


Keynote Presentation: Capital Markets Outlook
Marshall Smith, Head of Global Healthcare, Goldman Sachs


Investor Panel: Macro Trends, Market Corrections and Unmet Medical Need

What are the factors currently fuelling VC and public markets, how are these affecting the entrepreneurial scene and more well established firms and how do executives see these impacting appetite and strategies for investing and company building? Plus, with prominent reloads, what areas are grabbing investor’s attention?

Moderator: Paul Spreen, EVP and Chief Customer Officer, IQVIA 
Todd Foley
, Managing Partner, MPM Capital

Ricky Sun, Partner, Life Sciences, Bain Capital
Meredith Fisher, Partner, Partners Healthcare
Alan Crane, Entrepreneur Partner, Polaris Partners
Joshua Resnick,
Managing Partner, RA Capital Management


Pharma Panel: Strategic Shifts in Addressing Pipeline Drift; Pharma M&A and Partnering in 2020

Not withstanding the legacy factors continuing to influence strong deal flow, how is Pharma responding to the emerging encroachment of tech giants into their territories? Does this present co-operation opportunities or unwelcome competition and how will this impact external M&A, partnering and consolidation strategies?

Moderator: Jerry Lee, Managing Director, Goldman Sachs
Veronique Riethuisen, SVP, Global Head of Business Development & Alliance Management, Ipsen
Philippe Lopes-Fernandes, SVP, Global Head of BD & Alliance Management, Merck KGaA
Nigel Sheail, Global Head of Mergers & Acquisitions and Business Development & Licensing, Novartis


Networking Break


Corporate Investor Panel: Nothing Ventured, Nothing Gained; Backing Bigger Rounds and Making Bigger Bets

With the size of the average investment rounds getting bigger across the entire venture industry how are CVCs aligning with this trend? What can we expect to see from CVCs in terms of leading investment rounds and how is the macro environment affecting the approaches CVCs are taking. Plus, executives share some insights into their current investment preferences.

Moderator: Derek Stoldt, Co-head, M&A and Life Sciences Transactions Practice, Arnold & Porter
Peter Dudek
, Partner, MRL Ventures Fund

Priyanka Rohatgi, Managing Director, Head, Ipsen Ventures
Adam Houghton, Vice President and Head, AbbVie Ventures
Aaron Nelson,
Principal, Novartis Venture Fund
Laura Tadvalkar, Principal, MP Healthcare Venture Management (MPH)


Executive Panel: Raising the Bar; Making the ‘Series’ A Grade

In an industry becoming increasingly defined by weighty Series A’s, executives who have been instrumental in achieving strategically significant early-stage venture raises share their success stories and war stories in equal measure. Plus, share what we can expect to see from their companies as they continue to deploy their capital.

Moderator: Ori Solomon, Partner, Corporate Department and Co-chair, Emerging Companies and Venture Capital, Morrison Foerster
David De Graaf
, CEO, Comet Therapeutics
Alexandra Glücksmann, CEO, Cedilla Therapeutics
Michael Pavia
, CEO, Tuned Therapeutics                                                             

Andrew ElBardissi, Principal, Deerfield Management


Presentation: Leveraging Strategic Partnerships to Accelerate the progress of your molecule(s)

Experienced practitioners understand that the commonly used schematic representation of drug discovery and development as a ‘pipeline consisting of chevrons in sequence’ is an oversimplification at best. This session moderated by a CRO with 25 years of experience in drug discovery and development brings together a group of industry veterans to discuss how to leverage strategic partnerships to accelerate your drug discovery and development programs.

Kenneth Barr, SVP, Head of Discovery Services, Syngene

LSX Pharma BD Forum 200x    Licensing and collaboration workshop-1LSX Clinical Workshop 200x LSX 1-2-1 Partnering 200x

See a full description here


Networking Lunch


Executive Panel: De-Risking the Regulatory Approval Path - How to Optimize Your Investment Dollars

The path to global product approval is notorious for hurdles from every angle; from technical/scientific risk to regulatory and market access risk. The hurdles are even more evident when there is limited or no precedent for the indication being sought that could impact time, cost and approvability. Executives explore the best ways to minimize these risks and probe cases that address these issues during development, sharing de-risking strategies for keep innovative programs on track.

Moderator: Laurie Smaldone Alsup, MD, CSO, NDA Group
Ed Kaye, CEO, Stoke Therapeutics
Ailis Tweed-Kent, CEO, Cocoon Biotech

John Glasspool, CEO, Anthos Therapeutics
Christine Swenson
, Head, Regulatory Affairs, Moderna Therapeutics


Presentation: Partnering with J&J: The Why, How and What

Anjali Kumar, External Innovation Search and Evaluation, Eastern United States, Johnson & Johnson Innovation, Boston 


Keynote Chat: The Rationale of AI in Healthcare? It’s Human Nature
Ted Tanner Jr., CTO and Chief Architect, Watson Health, IBM
Jay Sales, 
Director, Advanced Technology, VSP Global


Presentation: Commercialization: Alternative to a traditional exit plan

The importance of a robust development and commercialization strategy has never been more evident. This presentation will outline the considerations needed as your drug progresses through the developmental phases towards the market and share advice on how to minimize the risk that your company’s therapy will end up a commercial failure.

Darin DeCarlo, Senior Principal and Segment Lead, IQVIA

LSX Pharma BD Forum 200x      Value Pricing-1LSX 1-2-1 Partnering 200x

See a full description here


Networking Break


Executive Panel: Movers, Shakers and Therapeutic Deal Makers

With lofty biotech valuations and rising competition in key therapeutic fields, executives who have positioned their companies as attractive for deal making opportunities share their experiences, KSFs and fundamentals when engaging big pharm. Plus executives share what we can expect to see from their respective companies in the year ahead.

Moderator: Farah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati
Rogerio Vivaldi
, CEO, Sigilon Therapeutics

Kelly Gold, Vice President, Corporate Development, CAMP4 Therapeutics
Nouhad Husseini, Vice President, Head of Business Development, Regeneron Pharmaceuticals
Chinoporos, CBO, Boston Pharmaceuticals


Closing Panel: Knocking on the Door; the Booming Direct-to-Consumer (D2C) Healthcare Model

With tech players increasingly encroaching in healthcare, forcing companies — as well as startups — to think of different ways to reach patients, and investors wagering that consumers will be increasingly willing to shop for healthcare the same way they buy more traditional products online, what can we expect from the D2C model?

Moderator: John Hodgson, Director, PersComm Ltd.
Alex Bargar, VP of Clinical Services, Simple Health
Melissa Fensterstock, Co-Founder and CEO, Lansdowne Labs
Carolyn Witte, Co-Founder and CEO, Tia
Nicole Bocskocsky, VP of Clinical Operations, Parsley Health


Close of Conference